STK11 and cancer: Research focused on NSCLC with KRAS driver mutations, in particular, the KRAS p.G12C mutation, shows that co-mutations in STK11 and/or KEAP1 make these cancers notably resistant to standard therapies, including targeted and immune-based treatments.